Related Tags >> FDA Phase III HIV/AIDS Merck

HIV/AIDS News

Most Popular HIV/AIDS Story

Selzentry approval marks big win for Pfizer

August 7, 2007 — 6:59am ET

Pfizer won accelerated approval from the FDA for Selzentry, the first HIV therapy in a new class of drugs in a decade. The drug (maraviroc) is a CCR5 antagonist, which prevents the virus from... Read more...

HIV/AIDS Press Releases

T cell-based HIV vaccine candidate demonstrates positive results
New hope for HIV treatment: Cells exhausted from fighting HIV infection can be revitalized
New York City Mayor Bloomberg, Honorees Celebrate First Laboratory Solely Devoted to the Development of an AIDS Vaccine
Pfizer's Novel HIV/AIDS Treatment Selzentry (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naïve HIV Patients
FDA Approves Tibotec Therapeutics's PREZISTA Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1

Latest Headlines

Time to rewrite AIDS vaccine playbook
August 7, 2008
Merck puts HIV development program on hold
July 28, 2008
Feds halt HIV vaccine human trial in latest setback
July 18, 2008
ALSO NOTED: Neurochem pursues new Kiacta trial; Teva drug fails ALS trial; Columbus tapped as promising new life sciences hub;
March 13, 2008
Panacos surges on HIV response data
March 6, 2008
NeurogesX pain patch fails a late-stage trial
February 28, 2008
BioAlliance undeterred by move to shelve trial
February 25, 2008
Idenix reports success in early-stage HIV drug trial
February 7, 2008
Scientists examine Selzentry's ability to stop HIV
January 30, 2008
Theratechnologies explores sale, other options
January 29, 2008
RNAi screening finds 273 proteins used by HIV
January 11, 2008
Incyte causes stir with experimental drug data
January 9, 2008
Trimeris to axe R&D ops in '08 restructuring
December 11, 2007
ALSO NOTED: Merck gets OK for new type of HIV drug; Hycamtin is approved; Labopharm appeals FDA decision; and much more...
October 15, 2007
Selzentry approval marks big win for Pfizer
August 7, 2007
Press Release: Medivir Announces BMS has Terminated Their Agreement for MIV-170
July 6, 2007
BMS sees positive outcome for cancer drug
July 6, 2007
HIV prevention trials halted on safety concerns
January 30, 2007
Deadly TB strain may be spreading fast in Africa
January 28, 2007
SPOTLIGHT: Avexa gains rights to HIV drug
January 22, 2007

Paid Research Reports